This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dyer, S. L. Articles by Meachan, B. Search for Related Content PubMed PubMed Citation Articles by Dyer, S. L. Articles by Meachan, B. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Pain Social Bookmarking                         What's this?

Insuflon Versus Subcutaneous Injection for Cytokine Administration in Children and Adolescents: A Randomized Crossover Study

University of South Australia, Hematology/Oncology Unit, Women’s and Children’s Hospital, South Australia, dyers{at}mail.wch.sa.gov.au

Carmel T. Collins, GDPH, BSSc, RN, RM, NICC

Department of Nursing and Midwifery Research and Practice Development, Women’s and Children’s Hospital, South Australia

Peter Baghurst, PhD, MSc, B AgSc

Public Health Research Unit, Women’s and Children’s Hospital, Departments of Public Health and Pediatrics at the University of Adelaide

Ben Saxon, MBBS, FRACP

Department of Clinical Hematology, Women’s and Children’s Hospital, South Australia

Brooke Meachan, RN

Hematology/Oncology Unit, Women’s and Children’s Hospital, South Australia

Pain is a frequent complication of subcutaneous cytokine injections in children. A randomized crossover trial was conducted to determine the least painful and preferred method of cytokine administration for children and young people. The current standard practice of subcutaneous injection was compared with the use of Insuflon (Maersk Medical, Roskilde, Denmark), a subcutaneous indwelling catheter. Children aged between 1 month and 18 years undergoing treatment within the oncology/hematology unit of a single tertiary hospital and receiving cytokines were eligible for the study. Twenty children participated in the study, each child receiving both administration methods in random order during sequential cytokine treatment courses. There was a trend toward higher pain scores when using subcutaneous injections for drug administration compared to Insuflon. Seventy-five percent (n = 15) of the children who completed the trial and their families preferred using Insuflon for subcutaneous drug administration. Consideration needs to be given, however, to those who refused to enter the study, withdrew, or continued because of a preference for subcutaneous injections. Current practice at the Women’s and Children’s Hospital is to allow the child and parents to choose their preferred treatment modality for subcutaneous drug administration.

Key Words: child • injection • Insuflon • oncology/hematology • subcutaneous

Journal of Pediatric Oncology Nursing, Vol. 21, No. 2, 79-86 (2004)
DOI: 10.1177/1043454203262680


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?